The drug selection process in our International Linked Clinical Trials (iLCT) programme is governed and evaluated by a committee of world leading scientists, physicians and advocates, all experts in their field of Parkinson’s research.

The iLCT Committee

Learn More

 Chair iLCT committee
Professor David K. Simon

Learn More

 Co-chair iLCT committee
Professor Camille Carroll

Learn More
Professor Roger Barker

Learn More
Patrik Brundin, M.D., Ph.D.

Learn More
Mark R. Cookson, M.D.,Ph.D.

Learn More
Professor David T. Dexter

Learn More
Professor David Devos

Learn More
Ted Dawson, M.D., Ph.D.

Learn More
Howard Federoff, M.D., Ph.D.

Learn More
Brian Fiske, Ph.D.

Learn More
Professor Tom Foltynie

Learn More
Susan Fox, PhD, MB BCh

Learn More
Tim Greenamyre, M.D., Ph.D.

Learn More
Karl Kieburtz, M.D., MPH

Learn More
Jeffrey H. Kordower Ph.D

Learn More
Dimitri Krainc, M.D.

Learn More
Darren Moore Ph.D.

Learn More
Michael Schwarzschild, M.D., Ph.D.

Learn More
David Sulzer, M.D.

Learn More
Professor Per Svenningsson

Learn More
Caroline Tanner, M.D., Ph.D., F.A.A.N.

Learn More

 Director of Clinical Development
Dr Richard Wyse MBE

Learn More

 Director of Research
Dr Simon Stott

Related content